Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways by Jingjing Hou et al.
Computational and Structural Biotechnology Journal 18 (2020) 125–136journal homepage: www.elsevier .com/locate /csbjInhibition of protein FAK enhances 5-FU chemosensitivity to gastric
carcinoma via p53 signaling pathwayshttps://doi.org/10.1016/j.csbj.2019.12.010
2001-0370/ 2019 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: GC, gastric cancer; 5-FU, 5-fluorouracil; FAK, Focal adhesion
kinase; shRNA, small hairpin RNA; OS, Overall survival; FP, first progression.
⇑ Corresponding authors at: Department of Gastrointestinal Surgery, Institute of
Gastrointestinal Oncology, Zhongshan Hospital of Xiamen University, Xiamen,
Fujian, China (Jingjing Hou); Fujian Province Key Laboratory of Advanced Materials
Oriented Chemical Engineering, College of Chemistry and Materials Science, Fujian
Normal University, Fuzhou, Fujian, China (Qian Feng); Urologic Medical Center,
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine,
Shanghai, China (Zhong Wan); Clinical and Translational Research Center, Shanghai
First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai,
China (Yongsheng Yu).
E-mail addresses: jjhou@xmu.edu.cn (J. Hou), fengqiangrace@fjnu.edu.cn
(Q. Feng), smmuwz@126.com (Z. Wan), yongshengyu@tongji.edu.cn (Y. Yu).
1 These authors contributed equally to this work.Jingjing Hou a,1,⇑, Yuyu Tan d,1, Chen Su a,1, Tao Wang e,1, Zhixing Gao f, Dan Song g, Jiabao Zhao a,
Yueting Liao h, Xiaotian Liu h, Ying Jiang i, Qian Feng j,⇑, Zhong Wan c,⇑, Yongsheng Yu b,⇑
aDepartment of Gastrointestinal Surgery, Institute of Gastrointestinal Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China
bClinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
cUrologic Medical Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
dDepartment of Biomedical Engineering, School of Electrical Engineering, University of South China, Hengyang, Hunan, China
eDepartment of Urology Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
fXiamen XICO Biotech Co., Ltd, Xiamen, Fujian, China
g State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian, China
hDepartment of Blood Transfusion, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China
iWest China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichaun, China
j Fujian Province Key Laboratory of Advanced Materials Oriented Chemical Engineering, College of Chemistry and Materials Science, Fujian Normal University, Fuzhou, Fujian, China
a r t i c l e i n f oArticle history:
Received 21 May 2019
Received in revised form 17 December 2019
Accepted 18 December 2019
Available online 30 December 2019
Keywords:
Gastric carcinoma
FAK
RNA interference
5-FU
Chemosensitivitya b s t r a c t
The small molecule drug 5-fluorouracil (5-FU) is widely used in the treatment for gastric cancer (GC),
however, it exerts poor efficacy and is associated with acquired and intrinsic resistance. Focal adhesion
kinase (FAK), a non-receptor tyrosine kinase, plays a key role in adhesion, migration, and proliferation of
gastric carcinoma cells, suggesting that this kinase may be a promising therapeutic target. Differentially
expressed FAK in GC tissue was detected by RT-qPCR and TCGA database analysis. To investigate the bio-
logical functions of FAK, loss-of-function experiments were performed. CCK-8 assay, colony formation
assay, flow cytometry, dual-luciferase reporter assays, and western blot assays were conducted to deter-
mine the underlying mechanisms of FAK in 5-FU chemosensitivity in GC. FAK is overexpressed in GC
patients, and positively correlated with poor prognosis. The use of shRNA interference to target FAK
decreased proliferation and increased apoptosis of GC cells in vitro. Importantly, FAK silencing enhanced
the therapeutic efficacy of 5-FU, leading to reduced tumor growth in vivo. We further demonstrated that
FAK silencing increased 5-FU-induced caspase-3 activity, and promoted p53 transcriptional activities.
Clinical data also has shown that patients with higher levels of FAK had significantly shorter overall sur-
vival (OS) and time to first progression (FP) than those with lower levels of FAK. These findings indicate
that FAK plays a critical role in 5-FU chemosensitivity in GC, and the use of FAK inhibitors as an adjunct to
5-FU might be an effective strategy for patients who undergo chemotherapy.
 2019 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastric carcinoma (GC) is the fifth most common malignancy
and third leading cause of cancer-related death [1]. Surgical exci-
sion and systemic chemotherapy are the primary treatment
options for metastatic gastric carcinoma [2–4]. Although the
chemotherapeutant 5-fluorouracil (5-FU) is largely used for medi-
cal treatment of gastric carcinoma, it exerts chemoresistance, lead-
ing to the failure of chemotherapy [5]. Therefore, it is important to
identify molecular markers and study the signal pathways that
modulate gastric carcinoma chemoresistance.
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process. Migration, invasion, and metastasis are important features
of malignant tumors. Tumor cells must adhere to the extracellular
matrix (ECM) and subsequently undergo migration. In recent years,
investigators have investigated the modulating effects of cell-ECM
interactions on the chemosensitivity of anti-cancer drugs [6–8].
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor tyrosine
kinase that regulates cell-cell and cell-ECM signal transduction. In
response to mechanical stimulation, FAK is phosphorylated [9–11]
on a catalytic loop [12], and the active form of FAK catalyzes sub-
sequent downstream signaling [11,13–15]. FAK is overexpressed in
several cancers, including breast, oral, colon, gastric, and ovarian
cancer. FAK plays an important role in tumor proliferation, migra-
tion, invasion, survival, and apoptosis [16–18], and also modulates
cell and ECM adhesion, as well as cytoskeleton recombination. The
ECM-integrin-cytoskeleton complex is the basic structure of inte-
grated signal transduction [19]. FAK regulates cell adhesion and
inhibits apoptosis through a variety of signaling pathways, all of
which affect the sensitivity of chemotherapy. FAK might be a key
factor that mediates tumor chemoresistance in gastric cancer,
making it a promising therapeutic target.
In this study, we investigated the potential roles of FAK in 5-FU
chemosensitivity in gastric carcinoma. We used q-PCR assay to
determine that FAK was overexpressed in gastric cancer patients
and the levels of overexpression correlated with poor prognosis.
We found that FAK inhibition suppressed the growth of gastric
cancer cells, reduced xenograft tumor growth in a nude mouse
model, and enhanced the therapeutic efficacy of 5-FU in the mouse
model. Mechanistically, we demonstrated that inhibition of FAK
enhanced apoptosis, increased 5-FU-induced caspase-3 activity,
and promoted p53 transcriptional activities. The expression levels
of p53 target gene p21, Bax, and PUMA were increased. These find-
ings showed that FAK plays a critical role in 5-FU chemosensitivity
in gastric carcinoma, and suggests an effective strategy for patients
who undergo chemotherapy.2. Materials and methods
2.1. RNA interference
Recombinant vectors expressing small hairpin RNA (shRNA)
against human FAK (Gene ID: 37233) were constructed by insert-
ing chemically-synthesized double-strand DNA fragments contain-
ing FAK-targeting shRNA sequences (control 50-shRNA GTC
TCCGAACGTGTCACGT-30); FAK shRNA-1: 50-GAACCTCGCAGT
CATTT-30; FAK shRNA-2: 50-GGAATGCTTCAAGTGTGCT-30) into-
plasmid pLentiLox3.7-nero at the HapI and XhoI sites, generating
the following plasmids: control shRNA, FAK shRNA-1 and FAK
shRNA-2. Recombinant lentiviral plasmids were cotransfected into
293 T cells with the packaging plasmids VSV-G, RSV-REV, and
pMDL. After 48 h the viral supernatants were passed through
0.45-lm filters and then used to infect target cells in the presence
of 6 lg/mL polybrene (Sigma-Aldrich).2.2. Cell culture, transfection, and treatment
Human gastric cancer BGC823 and SGC7901 cells were pur-
chased from ATCC (Manassas, VA, USA) and cultured in RPMI-
1640 (Gibco, Life Technologies, NY, USA) supplemented with 10%
fetal bovine serum (FBS, ExCell Bio, Shanghai, China), 100 U/ml
penicillin and 100 mg/mL streptomycin (Gibco). Plasmid DNA
transfection was performed with Turbofect reagent (Invitrogen,
CA, USA) according to the manufacturer’s instructions. 5-FU was
purchased from Sigma and was added to subconfluent cells at
the indicated doses.2.3. Real-time quantitative PCR (qPCR)
For qPCR analyses of mRNA, reverse transcription was per-
formed with TRIzol (Invitrogen, Carlsbad, CA, USA) extracted total
RNAs using a ReverTra Ace-a Kit as per the manufacturer’s instruc-
tion (Toyobo, Tokyo, Japan). qPCR was performed using the SYBR
Green Real-Time PCR Master Mix (Toyobo) and the Step One Plus
Real-Time PCR system (Applied Biosystems Inc., Foster City, CA,
USA) according to the manufacturers’ protocols with primers as
follows:
p21-forward: 50-CTCTAAGGTTGGGCAGGGTG-30;
p21-reverse: 50-GAAGAAGGGTAGCTGGGGCTC-30;
Bax-forward: 50-GGGGACGAACTGGACAGTAAC-30;
Bax-reverse: 50-GGGGACGAACTGGACAGTAAC-30;
PUMA-forward: 50-CAGCTGCCCGCTGCCTA-30;
PUMA-reverse: 50- AGCGAGAGCGAGGGCTG-30;
Actin forward: GGACTTCGAGCAAGAGATGG;
Actin reverse: AGCACTGTGTTGGCGTACAG;
FAK forward: AGCAGCCGCACCTTATAAAGA;
FAK reverse: TCTTGTGGCAGTTGCAATTA.
2.4. Cell counting kit-8 (CCK-8) assay
Relative cell viability of BGC823 cells and SGC7901 transfected
with control shRNA, FAK shRNA-1 or untreated was measured with
a CCK-8 kit (Dojindo, Kumamoto, Japan). Briefly, cells were plated
into 96-well plates containing 100 lL of growth medium. Post-
transfection for 72 h, CCK-8 reagent (10 mL/well) was added and
incubated for 3 h at 37 C in a 5% CO2 incubator. The absorbance
was measured at 450 nm using a microplate reader. The cell viabil-
ity was calculated as follows: relative cell viability % = [(A1  AB)/
(A0  AB)]  100, where A1 is the absorbance of treatment group,
A0 is the absorbance of control group and AB is the absorbance of
the blank group.
2.5. Colony formation assay
Cells were first infected with control shRNA, FAK shRNA-1, FAK
shRNA-2, or untreated for 72 h, then 1 103 cells/well were seeded
in 6-well plates with medium changed every two days. Cells were
fixed with methanol and stained with crystal violet after 10 days.
Colonies were counted and analyzed for clonogenicity.
2.6. Tumor-bearing mice model
Four- to six-week-old male nude mice were obtained from the
Laboratory Animal Center of Xiamen University. The animals were
maintained on standard laboratory chow under a 12 h/12 h light/-
dark schedule, unless otherwise indicated. All animal experiments
were conducted according to protocols and guidelines approved by
the Xiamen University Institutional Animal Care and Use Commit-
tee. Mice were divided into three groups, five mice each group,
randomly. Mice were subcutaneously injected with 5  106
untransfected BGC823, FAK control shRNA BGC823 and FAK
shRNA-1 stable knockdown BGC823 cells. Intratumoral adminis-
tration of a dose of 10 mg/kg of 5-FU was injected every 3 days
starting from the fifteenth day after inoculation of cells. The xeno-
graft tumors of mice were monitored every 4 days with Vernier
calipers. The size was calculated as follows: (V) = a  b2  0.5,
where a is the minimum diameter, b is the maximum diameter.
Mice were sacrificed 30 days later.
2.7. Western blots
Cells or tissues were lysed in a lysis buffer and protein concen-
trations for cells or tissues lysates were measured using the BCA
Fig. 1. FAK is significantly upregulated in GC clinical samples. (A) qPCR assay. The mRNA expression levels of FAK in 20 clinical samples were examined by qPCR assay. (B)
Upregulated mRNA expression levels of FAK in the 20 gastric cancer cases shown in A. (C) Significant upregulation of FAK was observed in gastric cancer samples available in
TCGA RNA-Seq dataset (p < 0. 001, Wilcoxon signed rank test). The expression of FAK was increased by 1.97-fold in gastric cancer compared with NT gastric tissue. Data are
presented as RSEM (RNA-Seq expression estimation by Expectation-Maximization) normalized count. (D) Immunohistochemical analysis of FAK expression in gastric cancer
tissue (Test Group) and adjacent noncancerous gastric tissue (Control Group). Typical representative immunohistochemical results are shown. Scale bar, 100 lm. (E) A bar
graph representing the relative expression level of FAK in the GCT and ANLT groups, as evaluated by positive staining points (a paired-sample t-test was used to compare the
data from the two groups).
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or G250 (Sigma-Aldrich, St. Louis, MO, USA). Thirty micrograms
protein/lane whole cell lysates were electrophoresed in SDS-
PAGE and transferred to a PVDF membrane (Millipore, Billerica,
MA, USA). After blocking for 1 h at room temperature in TBST with
5% non-fat milk, the membranes were probed with the following
primary antibodies: FAK (1:2000 CST), p-FAK (1:500 CST), Cle –
PARP (1:1000 CST), actin (1:5000 Sigma). After washing three
times, the membranes were incubated with HRP-conjugated goatanti-mouse or anti-rabbit secondary antibodies, 1:5000 (BD). Then,
the chemiluminescence reaction was performed.
2.8. Annexin V-FITC/PI double staining assay by flow cytometry
Apoptosis was measured using Annexin V-FITC/PI (Ebioscience,
San Diego, USA) dual staining by flow cytometry. Briefly, cells
(1  105 /well) were seeded into 6-well plates and infected with
lentivirus mediated FAK shRNA-1 or sh-ctrl with or without
Table 1
The baseline characteristics of GC patients included in the analysis (n = 40).
Clinicopathological parameters FAK-expression p value
Case Low High
Age (years)
>=50 22 8 14 0.6582
<50 18 4 16
Gender
Male 22 7 16 0.5423
Female 18 5 13
Tumor size (diameter/cm)
>=4 16 4 12 0.1217
<4 24 8 16
TNM stage
T1–T2 16 5 11 0.0356
T3–T4 24 7 17
12 28
p < 0.05 represents significant differences.
Bold type indicates statistically significant difference.
Table 2
The detailed description of the GC patient tissues information (n = 40).
Number Gender Age Tumor size (diameter) TNM stage Pathological typing Pathological typing
1 Female 74 4 cm III adenocarcinoma Tubular adenocarcinoma
2 Male 45 <4 cm III adenocarcinoma Low adhesion adenocarcinoma
3 Female 78 <4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
4 Male 39 4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
5 Female 68 <4 cm IV adenocarcinoma Low adhesion adenocarcinoma
6 Male 57 4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
7 Female 50 <4 cm IV adenocarcinoma mucosal adenocarcinoma
8 Male 58 <4 cm III adenocarcinoma Tubular adenocarcinoma
9 Male 80 <4 cm IV adenocarcinoma Tubular adenocarcinoma
10 Male 57 <4 cm Ⅰ adenocarcinoma Tubular adenocarcinoma
11 Male 43 4 cm IV adenocarcinoma Low adhesion adenocarcinoma
12 Male 76 <4 cm III adenocarcinoma Low adhesion adenocarcinoma
13 Male 43 <4 cm III adenocarcinoma Tubular adenocarcinoma
14 Male 66 <4 cm Ⅱ adenocarcinoma Low adhesion adenocarcinoma
15 Female 49 <4 cm III adenocarcinoma Tubular adenocarcinoma
16 Female 44 4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
17 Male 57 <4 cm IV adenocarcinoma Tubular adenocarcinoma
18 Female 74 <4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
19 Male 48 <4 cm IV adenocarcinoma Low adhesion adenocarcinoma
20 Male 64 4 cm Ⅱ adenocarcinoma Low adhesion adenocarcinoma
21 Male 44 <4 cm IV adenocarcinoma Low adhesion adenocarcinoma
22 Male 68 4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
23 Female 47 4 cm IV adenocarcinoma Tubular adenocarcinoma
24 Female 70 4 cm III adenocarcinoma Tubular adenocarcinoma
25 Male 46 4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
26 Female 47 <4 cm III adenocarcinoma Papillary adenocarcinoma
27 Male 60 <4 cm III adenocarcinoma Mucosal adenocarcinoma
28 Female 49 <4 cm Ⅱ adenocarcinoma Mucosal adenocarcinoma
29 Female 82 4 cm III adenocarcinoma Tubular adenocarcinoma
30 Male 63 4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
31 Female 73 4 cm III adenocarcinoma Papillary adenocarcinoma
32 Female 43 4 cm III adenocarcinoma Tubular adenocarcinoma
33 Male 67 <4 cm Ⅱ Adenocarcinoma Tubular adenocarcinoma
34 Male 59 <4 cm Ⅰ adenocarcinoma Tubular adenocarcinoma
35 Male 49 4 cm III adenocarcinoma Tubular adenocarcinoma
36 Female 41 <4 cm III adenocarcinoma Mucosal adenocarcinoma
37 Female 62 4 cm IV adenocarcinoma Papillary adenocarcinoma
38 Female 47 <4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
39 Female 45 <4 cm Ⅱ adenocarcinoma Tubular adenocarcinoma
40 Male 46 <4 cm III adenocarcinoma Mucosal adenocarcinoma
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FACS buffer (PBS containing 2% FBS), and labeled with Annexin V-
FITC for 30 min at 4 C in the dark and then with PI. The stained
cells were analyzed by flow cytometry (LSRFortessa, Becton Dick-
inson, San Jose, CA, USA). The filters used in the flow cytometry
were: DAPI: 450 BP 40, FITC: 525 BP40.2.9. Luciferase reporter assay
BGC823 cells were transfected in 6-well dishes at 80% conflu-
ence with 0.5 lg of various reporters, together with other plasmids
in various combinations as indicated. Each sample was supple-
mented with 0.5 lg of pCMV5-LacZ expressing b-galactosidase,
Fig. 2. FAK is a prognostic marker for survival of patients with gastric cancer. Kaplan-Meier curves stratified by the indicated mRNA levels, and tested by a log-rank test. High
levels of FAK correlated with poor overall survival (OS). (A) and poor time to first progression (FP). (B) in gastric cancer. Overall survival (OS). (C) and poor time to first
progression (FP). (D) in gastric cancer samples treatment with 5-FU.
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luciferase activity was measured at 24 h after transfection. All
transfections experiments were performed at least five times in
triplicate, and the error bars represented SD of the means.
2.10. TCGA analysis
We used mRNA expression array datasets from TCGA to explore
gene expression profiles in human cancer. We downloaded data
from 375 tumor tissues and 32 normal tissues of mRNA expression
data to determine differences in transcription levels of FAK
between normal gastric tissues and GC tissues. The data regarding
mRNA expression were produced on the platforms of Illumina
Infinium Human Methylation450 BeadChip and Illu-
minaGA_RNASeqV2.1.0.0 (Illumina, Inc., San Diego, CA, USA).
2.11. Survival analysis
Overall survival (OS) and first progression (FP) curves were cal-
culated with the Kaplan–Meier method to evaluate the prognosticvalue of FAK1 mRNA expression in GC (Gastric Cancer). A total of
876 GC patients were recruited from the Kaplan–Meier Plotter
online database. Subjects were divided into two groups by median
expression (high vs. low expression) and assessed by a Kaplan-
Meier survival plots, with the hazard ratio (HR) with 95% confi-
dence intervals (CI) and logrank P value calculated as in previous
reports [20,21].2.12. Clinical samples
All clinical samples were collected with the informed consent of
the patients and study protocols that were in accordance with the
ethical guidelines of the Declaration of Helsinki (1975) and were
approved by the Institutional Medical Ethics Committee of Xiamen
University. GC pathological diagnosis was verified by at least two
specific pathologists. 40 human GC specimens and paired adjacent
epithelial tissues were obtained from the Shanghai Outdo Biotech
Co., Ltd.
Fig. 3. FAK suppression inhibits proliferation in BGC823 cells. (A) mRNA expression levels of FAK measured by qPCR. (B) Protein expression of FAK by western blot. (C)
Statistical analysis of B. (D) The viability of BGC823 cells was determined using CCK-8. (E) Colony-formation assay performed with BGC823-control and BGC823-shFAK cells.
(F) Statistical analysis of E. Results are representative of three independent experiments, and the error bars represent the standard deviation (SD). *p < 0.05, ** p < 0.01,
*** p < 0.001.
130 J. Hou et al. / Computational and Structural Biotechnology Journal 18 (2020) 125–1362.13. Statistical analysis
Values represent the mean ± standard deviation (SD) of at least
three independent experiments. One-way ANOVA with Bonfer-
roni’s post-test was used for multiple comparisons and the Stu-
dent’s t test (two-tailed) was used for pair-wise comparisons.
Correlation analyses were performed with Pearson’s test. p values
<0.05 were considered statistically significant.
3. Results
3.1. FAK is significantly upregulated in human gastric cancer clinical
samples
To explore the function and relationship between the expres-
sion of FAK and gastric carcinogenesis, we performed qPCR on 20
pairs of clinical samples. As shown in Fig. 1A–B, in 60%–70% of
the human gastric cancer (GC) tissues, FAK was significantly upreg-ulated compared to the levels in normal tissues (13 out of 20). We
then used the TCGA cancer microarray mRNA database to identify
the FAK expression levels in gastric cancer. The results showed that
the FAK gene was significantly more highly expressed in gastric
cancer (Fig. 1C). Immunohistochemical analysis showed that FAK
was diffusely expressed in the cytoplasm. FAK was expressed in
28/40 (70%) of GC tissues, with expression levels that were higher
in GC than in adjacent noncancerous gastric tissues (Fig. 1D). The
relative expression levels of FAK in the GC tissue group and the cor-
responding pathologically noncancerous gastric tissue group (Con-
trol group) were evaluated. We observed a statistically significant
increase in FAK expression in the GC group compared with the
level in the control group (Fig. 1E). Further analysis in Table 1
showed that FAK level was correlated to tumor-node-metastasis
TNM staging (n = 40, p < 0.05), while no apparent association
was found between FAK expression with patient gender, patient
age, tumor size. The detailed description of the patient information
is shown in Table 2 (Age, Tumor size, Clinical staging, ect.).
Fig. 4. FAK silencing enhances 5-FU chemosensitivity in BGC823 cells. BGC823 cells were infected with lentivirus expressing control or FAK-shRNA plasmids, and the cells
were untreated or treated with 5-FU for an additional 24 h. (A) Flow cytometry to determine cell apoptosis. (B) Statistical analysis of the apoptosis ratio in the various groups
as indicated. (C) Western blot analysis of the indicated proteins. The Cle-PARP expression was quantify and statistically analyzed using image analyzer. Results are
representative of three independent experiments, and the error bars represent the SD. *p < 0.05, ** p < 0.01.
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cancer
Because FAK was significantly upregulated in GC clinical sam-
ples, we asked whether the FAK gene could serve as a prognostic
marker in GC patients. Therefore, overall survival (OS) and first
progression (FP) curves were plotted using the Kaplan–Meier
method based on the gene expression level in 882 GC samples.
Patients with higher levels of FAK1 had significantly shorter OS
(Fig. 2A, logrank P = 2.2  106) and FP (Fig. 2B, logrank P = 1.5  1
05) than those with lower levels of FAK. A similar result was also
found in survival analysis according to gene expression levels in
153 GC patient samples treated with 5-FU (Fig. 2C-D). These resultsshowed that FAK is closely related to the prognosis of the patient
with gastric cancer.
3.3. Knockdown of FAK suppressed BGC823 cell proliferation
To evaluate the effects of FAK on gastric carcinogenesis, we used
a lentivirus construct to knock down FAK and performed transfec-
tion studies in BGC823 gastric cancer cells with two plasmids, FAK
shRNA-1 and FAK shRNA-2. After 72 h transfection, we measured
mRNA and protein levels of FAK. As shown in Fig. 3A-C, compared
to the control shRNA group, FAK mRNA expression was reduced
by 73.4% and 62%, respectively (p < 0.001, p < 0.01), and protein level
was reduced by 62.4% and 49.2%, respectively (p < 0.01, p < 0.05) in
Fig. 5. Downregulation of FAK increases 5-FU-induced apoptosis. BGC823 cells were infected with the lentivirus expressing control or FAK-shRNA plasmids, and the cells
were untreated or treated with 5-FU for an additional 24 h. (A). Cell viability was determined by CCK-8. (B) Caspase-3 activation assay. (C) Luciferase reporter assays of p53RE,
p21, and Bax. (D) qPCR analysis of Bax, p21, and PUMA mRNA expression. Results are representative of three independent experiments, and the error bars represent the SD.
*p < 0.05, **p < 0.01.
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To evaluate the effects of inhibition of FAK on BGC823 cells, CCK-8
assay was next used to examine the relative amount of cell prolifer-
ation after FAK knockdown. As shown in Fig. 3D, FAK knockdown
significantly inhibited proliferation of BGC823 cells by 60% com-
pared to the control group. Consistently, colony formation assay,
as shown in Fig. 3E–F, indicated that the rate of proliferation of
shRNA-FAK cells was reduced relative to that of shRNA-Ctrl cells
(p < 0.05, vs control group). Taken together, these results demon-
strated that inhibition of FAK significantly inhibited the prolifera-
tion BGC823 cells and enhanced oncogenic transformation.
Because the FAK shRNA-1 has a more dramatic effect compared to
shRNA-2, we selected shRNA-1 (named FAK shRNA) for subsequent
experiments. Consistent results were obtained in analysis of
SGC7901, another gastric cancer cell line (Supplementary Fig. 1).
3.4. FAK silencing enhanced 5-FU chemosensitivity in BGC823 cells
We next performed Annexin V-FITC assay to investigate the
effect of FAK on 5-FU-induced BGC823 apoptosis. The flow cytome-try results showed a significant increase in 5-FU-induced apoptosis
comparedwith control cells.We found 5-FU treatment alone caused
a 31.9% apoptotic rate, but the percentage of apoptotic cells induced
by 5-FU increased to 56% after FAK silencing (Fig. 4A–B). The results
suggest that FAK silencing enhanced 5-FU chemosensitivity in vitro.
Consistently, the western blot results showed that FAK inhibition
enhanced 5-FU-induced BGC823 apoptosis (Fig. 4C). In summary,
these data demonstrated that FAK silencing enhanced 5-FU
chemosensitivity.
3.5. Downregulation of FAK enhanced p53 activation after treatment
of 5-FU
As shown in Fig. 5A, we examined the proliferation of control
group cells and FAK-shRNA group cells after 5-FU treatment for
24 h. Compared with control groups, FAK-shRNA groups
showed decreased proliferation and enhanced caspase-3 activity
(Fig. 5A–B).
Because knockdown of FAK increased 5-FU-induced apoptosis,
we next examined the p53 signaling pathway since it is related
Fig. 6. FAK inhibition suppresses tumor growth in nude mice. (A) Time-dependent tumor growth alterations in nude mice. (B and C) Statistical analysis of the tumor weight of
each group. (D) Expression of apoptosis-associated proteins in the tumors in each group. The Cle-PARP expression was quantify and statistically analyzed using image
analyzer. (E) Measurement index of xenografts in nude mice. Results are representative of three independent experiments, and the error bars represent the SD. *p < 0.05,
** p < 0.01.
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that 5-FU stimulation after knockdown of FAK increased activation
of several p53-target genes, including p53 RE, p21, and Bax
(Fig. 5C). We also detected mRNA expression levels of p53-target
genes, including Bax, p21, and PUMA. The results demonstrate that
FAK-shRNA groups showed much stronger p53 transcriptional
activities than control groups, both in the absence and presence
of 5-FU (Fig. 5D). Overall, these results demonstrated that inhibi-
tion of FAK enhanced 5-FU-induced p53 activation and promoted
the ability of 5-FU to inhibit gastric cancer proliferation.3.6. FAK inhibition suppressed xenograft tumor growth in nude mice
To examine the effects of FAK in gastric cancer development
in vivo, xenograft tumors were induced in 6–7 weeks nude mice
by a single injection of BGC823-untreated cells, BGC823-control
cells, or BGC823-FAK-shRNA cells at a dosage of 5  106. A signif-
icant amelioration in tumor size was observed in the FAK-shRNA
transfected group compared to the blank control group or the con-
trol shRNA transfected group over 16 days (p < 0.01) (Fig. 6A). At
day 30, mice were sacrificed and the xenograft tumors were
Fig. 7. Suppressed-FAK promotes 5-FU-induced cell proliferation inhibition in vivo. (A) The tumor growth curves for various groups of nude mice treated as indicated. (B)
Photographs of dissected xenograft tumors from various groups of nude mice treated as indicated. (C) Statistical analysis of the tumor weight of each group.. (D) Expression of
apoptosis-associated proteins in the tumors in each group. (E) Measurement index of xenograft for various groups of nude mice. Results are representative of three
independent experiments, and the error bars represent the SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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with the cells in which FAK was inhibited was 31% lower than the
tumor weight of the control group (p < 0.01). The volume inhibition
rate of the FAK inhibition group was 63% and the weight inhibition
was 51% compared with the control group (Fig. 6B–C, E). These
results showed that inhibition of FAK decreased tumor cell growth
dramatically.
Because FAK regulated cell proliferation and tumor develop-
ment, we investigated the potential signaling pathway of FAK
might affect tumorigenesis. Then, we performed western blot
assays to examine the apoptosis signaling pathways to further
explore the underlying molecular mechanisms. We found that
FAK inhibition markedly suppressed protein levels of phosphory-
lated FAK, but Cle-PARP was significantly upregulated (Fig. 6D).
These data revealed that FAK inhibition decreased gastric cancer
tumorigenesis and progression.3.7. Suppression of FAK increased the 5-FU-induced inhibition of cell
proliferation in vivo
To investigate whether FAK enhanced 5-FU chemosensitivity
in vivo, BGC823-control cells, BGC823-FAK-shRNA cells, or the cor-
responding cells treated with 5-FU were subcutaneously injected
into nude mice. After tumors reached approximately 100 mm3 in
size, mice were randomized to receive treatment with PBS or 5-
FU for 4 days of a 20-day period. The tumor size was measured
every 5 days for up to 30 days (Fig. 7A). We observed that 5-FU
treatment inhibited tumor development. With FAK silencing, the
tumor growth inhibition was more substantial, with a significant
decrease in tumor volume and weight compared with the control
cells. The tumor volume inhibition was increased from 58% to
69% and the weight inhibition rate was increased from 52% to
70% (Fig. 7B–C, E). We also found that FAK inhibition markedly
J. Hou et al. / Computational and Structural Biotechnology Journal 18 (2020) 125–136 135suppressed protein levels of phosphorylated FAK. Compared with
5-FU non-treatment group, Cle-PARP of treatment group was sig-
nificantly upregulated (Fig. 6D). These results demonstrated that
FAK silencing enhanced the chemosensitivity to 5-FU in vivo.4. Discussion
Gastric carcinoma (GC) is one of the most common malignant
tumors. The morbidity and mortality of GC have exhibited an
increasing tendency in recent years. Chemotherapy is a major
method used to treat GC [22–24], and 5-FU is commonly used in
clinical treatment, where it causes cell death by interfering with
nucleoside metabolism, DNA synthesis, and RNA dysfunction
[25]. Chemoresistance is a common phenomenon and is an impor-
tant factor affecting therapeutic efficacy and prognosis in cancer
therapy [26]. Drug resistance of tumor cells alters the microenvi-
ronment and decreases the effects of toxic components, leading
to decreased DNA repair activity and apoptosis [27,28].
FAK is a multi-function non-receptor tyrosine kinase that plays
a vital role in cell-cell and cell-ECM adhesion. FAK participates in
cell cycle regulation, survival, proliferation, apoptosis, migration,
invasion, metastasis, and other processes [16–18,29,30]. Impor-
tantly, FAK is closely associated with the development of tumors
in several cancers, and recent studies reported significantly
increased FAK expression levels in colon, liver, lung, gastric, breast,
and ovarian cancer [19,31–35]. Therefore, targeting FAK expression
may be an effective therapeutic option.
In this study, we found that inhibition of FAK expression
enhanced 5-FU chemosensitivity in GC. We used RNA interference
to knock down FAK in gastric carcinoma BGC823 and SGC7901
cells and determined the biological changes. We found that FAK
shRNA downregulated mRNA and protein expression of FAK and
led to decreased cell proliferation of gastric cancer cells based on
CCK-8 and colony formation assays. We also observed that FAK
RNA interference reduced xenograft tumor growth in a nude
mouse model. Additionally, the inhibition of FAK in BGC823 cells
enhanced the therapeutic efficacy of 5-FU. Taken together, these
results indicated that FAK attenuated gastric cancer cell prolifera-
tion, slowed the development of tumors, and, critically, improved
the sensitivity of 5-FU treatment. FAK inhibition also increased
5-FU-induced caspase-3 activity and promoted p53 transcriptional
activities. Most of our experiments were performed in BGC823
cells, and there may be some limitations of our conclusions, so
these results will need to be verified in future experiments. The
clinical data presented in Table 1 showed that FAK level was corre-
lated to TNM staging lymph and node status, while no apparent
association was found between FAK expression and patient gender,
patient age, or tumor size. These data showed that the FAK gene
may play an important role in GC development. At the same time,
database analysis revealed that patients with higher levels of FAK
had a significantly shorter overall survival (OS) and poor time to
first progression (FP) than did those with lower levels of FAK in
the absence or presence of 5-FU. High FAK expression promotes
tumor recurrence and reduces patient survival, which suggested
that FAK may be a prognostic marker of survival of patients with
gastric cancer and used as a potential target for tumor treatment
in the gastric cancers. Many early studies showed FAK contains
multiple phosphorylation sites, including tyrosine, lysine, and ser-
ine residues, and together with proteins that contain SH2 and SH3
domains, FAK participates in biological processes through integrin,
BRAF/MEK/ERK, Src/FAK, SFK-FAK/CSF-1R, FAK-ROCK/RhoA, FAK/
PI3K/Akt, and other pathways [36–40]. Although our results
demonstrated that p53 signaling pathways may be involved in
the FAK-mediated mechanisms of gastric cancer development,
whether FAK affects other signaling pathways to regulate gastriccancer progression is an important issue that requires further
study.
5. Conclusion
Inhibition of FAK increased 5-FU chemoresistance and pro-
moted apoptosis by inhibiting the p53 signaling pathway in gastric
carcinoma. Our results suggest an alternative mechanism for 5-FU
in gastric carcinoma and suggest that FAK silencing may serve as
an effective strategy for patients undergoing chemotherapy.
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